EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report

Luca Carlofrancesco Ammoni, Giorgia Carola, Giuseppe Ippolito, Alice Baggi, Francesca Consoli, Andrea Esposito, Ilaria Pedrazzini, Alfredo Berruti, Salvatore Grisanti

Frontiers in Oncology · 28.05.2026 · 16

DOI: 10.3389/fonc.2026.1840539 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 28.05.2026. Verfasst von Luca Carlofrancesco Ammoni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanit…. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) accounts for approximately 3–7% of all NSCLCs and predominantly affects young, never-smoker patients. Lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), has demonstrated significant efficacy as first-line therapy. However, its exclusive oral formulation poses a challenge in patients with dysphagia. Case presentation We report the case of a 30-year-old woman with metastatic ALK-positive NSCLC who presented with severe dysphagia due to bulky supraclavicular and laterocervical lymphadenopathy compressing the cervical oesophagus. Given the impossibility of swallowing, lorlatinib 100 mg daily was administered via a nasogastric tube after tablet crushing. Within days, rapid reduction of cervical lymph node swelling was observed, swallowing improved, and the patient resumed oral intake. Imaging performed two weeks later showed partial response; at six months, PET-CT demonstrated complete metabolic response.

Discussion

This case supports the feasibility and effectiveness of lorlatinib administration via the enteral route in patients unable to swallow. Despite the lack of formal evidence for alternative formulations, pharmacokinetic data suggest adequate absorption.

Conclusion

Crushed lorlatinib administered through a nasogastric tube represents a practical and effective option for dysphagic patients with ALK-positive NSCLC requiring early target-directed therapy.

Schlagwörter

Stichwörter der Autor:innen

ALK translocationdysphagiaenteral absorptionlorlatinibnon-small cell lung cancer

Autor:innen und Institutionen

  • Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili, Brescia, Italy.

Zitieren

APA

Ammoni, L. C., Carola, G., Ippolito, G., Baggi, A., Consoli, F., Esposito, A., Pedrazzini, I., Berruti, A., & Grisanti, S. (2026). Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1840539

Vancouver

Ammoni LC, Carola G, Ippolito G, Baggi A, Consoli F, Esposito A, et al. Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1840539

BibTeX
@article{Ammoni2026,
  author = {Ammoni, Luca Carlofrancesco and Carola, Giorgia and Ippolito, Giuseppe and Baggi, Alice and Consoli, Francesca and Esposito, Andrea and Pedrazzini, Ilaria and Berruti, Alfredo and Grisanti, Salvatore},
  title = {Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1840539}
}
Kostenlos starten →